Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an announcement.
Genflow Biosciences Plc has launched a new ophthalmology development program aimed at advancing a novel gene therapy using its proprietary Centenarian SIRT6 (cSIRT6). This initiative, which includes a Material Transfer Agreement with a leading ophthalmology company, focuses on developing a non-viral vector for precise delivery to the eye, targeting ocular diseases such as corneal pathologies and glaucoma. This move is part of Genflow’s broader strategy to optimize its gene therapy offerings and strengthen its position in the biotechnology industry by leveraging its unique SIRT6 technology.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a UK-based biotechnology company with R&D facilities in Belgium, focused on pioneering gene therapies to slow the aging process. The company aims to promote longer and healthier lives while addressing the impacts of an aging global population. Genflow’s lead compound, GF-1002, involves a centenarian variant of the SIRT6 gene, with promising preclinical results. The company is also exploring treatments for chronic liver disease and has initiated a clinical trial in aged dogs.
YTD Price Performance: -41.86%
Average Trading Volume: 1,184,001
Technical Sentiment Signal: Strong Buy
Find detailed analytics on GENF stock on TipRanks’ Stock Analysis page.